NDATOPICALSPRAY
Approved
Oct 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
6/8 — Strong
CLOBEX (clobetasol propionate) by Galderma is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown. Approved for psoriasis, atopic dermatitis. First approved in 2005.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLOBEX is a topical corticosteroid spray containing clobetasol propionate, a potent agent used to treat inflammatory skin conditions including psoriasis, atopic dermatitis, and seborrheic dermatitis. The drug modulates signaling, immune function, inflammation, and protein regulation, though its precise mechanism in corticosteroid-responsive dermatoses remains incompletely understood. It is administered as a spray for rapid, localized delivery to affected skin areas.
$0.135MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with minimal commercial footprint (150 Part D claims in 2023), suggesting a contracting team and reduced growth opportunities for traditional brand roles.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid responsive dermatoses is unknown.
Indications (2)
Clinical Trials (19)
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Started Dec 2022
60 enrolled
Cataracts Infantile
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Started Nov 2022
70 enrolled
Alopecia Areata
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Started Jun 2020
250 enrolled
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Started Jun 2020
215 enrolled
Cataract
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Started Jul 2013
28 enrolled
Plaque Psoriasis
Worked on CLOBEX at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.